NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Rating of “Hold” from Analysts

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have been given a consensus rating of “Hold” by the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.3333.

Several brokerages have recently commented on NMTC. LADENBURG THALM/SH SH raised their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings cut NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Finally, Maxim Group set a $5.00 price target on NeuroOne Medical Technologies and gave the stock a “buy” rating in a research report on Friday, August 14th.

Insiders Place Their Bets

In other news, Director Mark Christianson sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the sale, the director directly owned 20,692 shares in the company, valued at approximately $65,800.56. This represents a 32.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Legato Capital Management LLC bought a new stake in NeuroOne Medical Technologies during the fourth quarter worth about $34,000. Squarepoint Ops LLC bought a new position in NeuroOne Medical Technologies in the 4th quarter valued at about $36,000. Susquehanna International Group LLP bought a new position in NeuroOne Medical Technologies in the 2nd quarter valued at about $41,000. XTX Topco Ltd acquired a new position in shares of NeuroOne Medical Technologies in the 2nd quarter valued at approximately $51,000. Finally, BlackRock Inc. acquired a new position in shares of NeuroOne Medical Technologies in the 2nd quarter valued at approximately $76,000. Institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Performance

NASDAQ:NMTC opened at $2.03 on Monday. NeuroOne Medical Technologies has a 52 week low of $1.42 and a 52 week high of $6.96. The firm has a market cap of $18.49 million, a price-to-earnings ratio of -2.14 and a beta of 0.61. The firm’s 50-day simple moving average is $2.41 and its 200 day simple moving average is $3.66.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The business had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. Sell-side analysts anticipate that NeuroOne Medical Technologies will post -0.39 EPS for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.